Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma

Journal of Vascular and Interventional Radiology

Volumn 24, Issue 2, 2013, Pages 257-265

  Kalva, Sanjeeva P ^a   Pectasides, Melina ^a   Yeddula, Kalpana ^a   Ganguli, Suvranu ^a   Blaszkowsky, Lawrence S ^a   Zhu, Andrew X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MICROSPHERE;

ADULT; ARTICLE; CHEMOEMBOLIZATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR NECROSIS;

ANTIBIOTICS, ANTINEOPLASTIC; CAPSULES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MASSACHUSETTS; MIDDLE AGED; PREVALENCE; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84873205443     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.10.021     Document Type: Article

References (57)

1. M. Varela, M. Sala, J.M. Llovet, and J. Bruix Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev 29 2003 99 104
2. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
3. J.M. Llovet, M.I. Real, and X. Montaña Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
4. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
5. C. Cammà, F. Schepis, and A. Orlando Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 2002 47 54
6. J. Bruix, and M. Sherman American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
7. J.Y. Choi Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea Oncology 81 suppl 1 2011 141 147
8. K. Ahrar, and S. Gupta Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes Surg Oncol Clin N Am 12 2003 105 126
9. D.A. Leung, J.E. Goin, C. Sickles, B.J. Raskay, and M.C. Soulen Determinants of postembolization syndrome after hepatic chemoembolization J Vasc Interv Radiol 12 2001 321 326
10. F. Farinati, M. Rinaldi, S. Gianni, and R. Naccarato How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system Cancer 89 2000 2266 2273
11. K. Malagari, K. Chatzimichael, and E. Alexopoulou Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients Cardiovasc Intervent Radiol 31 2008 269 280
12. D.K. Reyes, J.A. Vossen, and I.R. Kamel Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States Cancer J 15 2009 526 532
13. A.L. Lewis, M.V. Gonzalez, and S.W. Leppard Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution J Mater Sci Mater Med 18 2007 1691 1699
14. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
15. H. van Malenstein, G. Maleux, and V. Vandecaveye A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma Onkologie 34 2011 368 376
16. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluLar carcinoma (HCC) J Surg Oncol 101 2010 476 480
17. D.B. Brown, B. Nikolic, A.M. Covey Society of Interventional Radiology Standards of Practice Committee Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy J Vasc Interv Radiol 23 2012 287 294
18. A. Forner, M.E. Reig, C.R. de Lope, and J. Bruix Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 2010 61 74
19. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators Hepatology 28 1998 751 755
20. M. Kudo, H. Chung, and Y. Osaki Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) J Gastroenterol 38 2003 207 215
21. T.I. Huo, C.Y. Hsia, and Y.H. Huang Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the Model for End-stage Liver Disease (MELD), MELD-sodium, and five cancer staging systems J Clin Gastroenterol 43 2009 773 781
22. J.M. Llovet, S. Ricci, V. Mazzaferro SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
23. B.I. Carr, V. Kondragunta, S.C. Buch, and R.A. Branch Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma Cancer 116 2010 1305 1314
24. M. Varela, M.I. Real, and M. Burrel Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
25. T.J. Vogl, J. Lammer, and R. Lencioni Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial AJR Am J Roentgenol 197 2011 W562-w570
26. M.J. Song, C.H. Park, and J.D. Kim Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients Eur J Gastroenterol Hepatol 23 2011 521 527
27. A. Nicolini, L. Martinetti, S. Crespi, M. Maggioni, and A. Sangiovanni Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma J Vasc Interv Radiol 21 2010 327 332
28. R. Sacco, I. Bargellini, and M. Bertini Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22 2011 1545 1552
29. M.D. Ferrer Puchol, C. la Parra, and E. Esteban Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma Radiologia 53 2011 246 253
30. K. Malagari, M. Pomoni, and A. Kelekis Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 541 551
31. B. Jin, D. Wang, and R.J. Lewandowski Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma AJR Am J Roentgenol 196 2011 919 928
32. I.F. Hsin, C.Y. Hsu, and H.C. Huang Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction J Clin Gastroenterol 45 2011 556 562
33. B.S. Shin, M.H. Park, and G.S. Jeon Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization Acta Radiol 52 2011 331 335
34. C. Lance, G. McLennan, and N. Obuchowski Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma J Vasc Interv Radiol 22 2011 1697 1705
35. H.T. Hu, J.H. Kim, and L.S. Lee Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort J Vasc Interv Radiol 22 2011 917 923
36. T.I. Huo, C.Y. Hsu, and Y.H. Huang Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy BMC Gastroenterol 10 2010 146
37. S.E. Mahady, B. Charlton, and P. Fitzgerald Locoregional therapies for hepatocellular carcinoma: Which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 25 2010 1299 1305
38. J.W. Zhang, X.Y. Feng, and H.Q. Liu CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE World J Gastroenterol 16 2010 2038 2045
39. M. Olivo, F. Valenza, and A. Buccellato Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors Dig Liver Dis 42 2010 515 519
40. A. Hiraoka, N. Horiike, and Y. Yamashita Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization Hepatogastroenterology 56 2009 213 217
41. J. Dumortier, F. Chapuis, and O. Borson Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients Dig Liver Dis 38 2006 125 133
42. J. Uraki, K. Yamakado, A. Nakatsuka, and K. Takeda Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors Eur J Radiol 51 2004 12 18
43. W. Lu, Y. Li, X. He, and Y. Chen Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors Hepatogastroenterology 50 2003 2079 2083
44. C.S. Liao, K.C. Yang, M.F. Yen, L.L. Teng, S.W. Duffy, and T.H. Chen Prognosis of small hepatocellular carcinoma treated by percutaneous ethanol injection and transcatheter arterial chemoembolization J Clin Epidemiol 55 2002 1095 1104
45. S. El Khaddari, J.L. Gaudin, H. Abidi, G. Picaud, A. Rode, and J.C. Souquet Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session Gastroenterol Clin Biol 26 2002 728 734
46. S. Maeda, S. Fujiyama, M. Tanaka, H. Ashihara, R. Hirata, and K. Tomita Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization Hepatol Res 23 2002 202 210
47. L. Lladó, J. Virgili, and J. Figueras A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization Cancer 88 2000 50 57
48. M. Colleoni, G. Liessi, and G. Mastrapasqua Prognostic factors in patients with hepatocellular carcinoma submitted to chemoembolization Oncol Rep 4 1997 1025 1028
49. F. Farinati, N. De Maria, and C. Marafin Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization Dig Dis Sci 41 1996 2332 2339
50. Y. Hatanaka, Y. Yamashita, and M. Takahashi Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management Radiology 195 1995 747 752
51. L. Mondazzi, R. Bottelli, and G. Brambilla Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors Hepatology 19 1994 1115 1123
52. H. Shijo, M. Okazaki, H. Higashihara, F. Koganemaru, and M. Okumura Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization Am J Gastroenterol 87 1992 1154 1159
53. M.Y. Hsieh, W.Y. Chang, and L.Y. Wang Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors Cancer Chemother Pharmacol 31 suppl 1992 S82 S85
54. K. Yamamoto, M. Masuzawa, M. Kato, T. Okuyama, and K. Tamura Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization Cancer Chemother Pharmacol 31 suppl 1992 S77 S81
55. M. Iñarrairaegui, A. Martinez-Cuesta, and M. Rodríguez Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma Int J Radiat Oncol Biol Phys 77 2010 1441 1448
56. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study HPB (Oxford) 12 2010 174 1780
57. J.H. Shim, H.C. Lee, and S.O. Kim Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718